(P-772) Retrospective, Multicenter Evaluation of Initial Therapy for Suspected Urinary-Source Sepsis in the Absence of Risk Factors for Ceftriaxone Resistance: Ceftriaxone versus Cefepime or Piperacillin-tazobactam

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Alice M. Landayan, PharmD, BCIDP

Clinical Pharmacy Coordinator; PGY-1 RPD; PGY-2 ID RPC
South Miami Hospital
South Miami, FL, United States
LM

Lourdes R. Menendez Alvarado, PharmD, BCIDP, BCPS

Baptist Health
Miami, Florida, United States
LA

Lee Amaya, PharmD, BCIDP, AAHIVP

Infectious Diseases Pharmacist
Miami Cancer Institute Baptist Health
Miami, Florida, United States
WF

Wilbert Fuerte, PharmD, BCIDP

Homestead Hospital
Homestead, Florida, United States
Timothy Gauthier, PharmD, BCPS, BCIDP

Clinical Program Manager, Antimicrobial Stewardship
Baptist Health South Florida
Miami, FL, United States